Cardiac ablation firm pulls in $5m series B
This article was originally published in Clinica
Advanced Cardiac Therapeutics (ACT) is preparing to initiate full European commercial launch of its cardiac ablation technology this year, after closing a $5m series B financing round. NBGI Ventures was the lead investor. ACT has developed an irrigated, radiofrequency cardiac ablation catheter, which incorporates a microwave radiometry technology that measures – in real time – ablation temperatures inside cardiac tissue. This gives the electrophysiologist better control when they are creating lesions with the ablation catheter, and potentially improves patient outcomes, says Laguna Beach, California-based ACT. Current irrigated cardiac ablation systems do not provide tissue temperature feedback, according to the firm.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.